Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balcinrenone/Dapagliflozin PK in Kidney Failure on Hemodialysis
NCT07754331Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of balcinrenone and dapagliflozin in kidney failure (ESRD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve from zero to infinity, Area Under the Curve from zero to last quantifiable concentration and 11 more. Started Aug 2026; status: completed.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
kidney failure (ESRD)
Beyond the preview
Go deeper on NCT07754331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754331.